Clinical Trial Update: Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis [Phase 1]

View source ↗

Summary

Phase 1 safety and biological efficacy study of TissueGene-C for osteoarthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• TissueGene-C (TG-C)

Snippet

Sponsor: Kolon Life Science | Conditions: Degenerative Arthritis | Phase 1 | Status: COMPLETED